Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
Anybody else getting these emails asking you to change your NO vote? I’ve gotten 7 separate responses! The desperation is ridiculous!!
***That’s why the board of directors is recommending the shareholders support their recommendation to vote IN FAVOR of the proposals. Would you be willing to change your Against vote to an IN FAVOR vote for the benefit of the company and the shareholders?
Jonathan Ulloa
Senior Proxy Voting Specialist
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003 -
I’ve now gotten 7 emails from Alliance Advisors, the proxy firm that’s handling the voting for ATOS, asking me to consider changing my no vote. WTF....
-
Volume has been at a near standstill for over an hour
-
866-612-8937 ATOS
Inquire as to why no PR has been released, told them my vote will be no unless some type of PR is given prior to the shareholder meeting. Said they would have someone call me.
Enough people start blowing them up they will get the picture.
-
You’re seeing the ineptness of management on full display.
-
Volume stagnant
-
866-612-8937 ATOS
Inquire as to why no PR has been released, told them my vote will be no unless some type of PR is given prior to the shareholder meeting. Said they would have someone call me.
Enough people start blowing them up they will get the picture.
-
During the GME and AMC fiasco, AMC released 500 million new shares into the market. It’s why they didn’t runup nowhere near what GME did. They made so much money off it they were able to decline the loan that was going to be extremely high on interest rate. Adding 325 million new shares to ATOS is going to have that same dampening effect on any runup from news dropping.
-
The increase in shares is to give them a compensation of 15 million in employee benefits. And an additional windfall from the sale of 325 million new shares. Which will not only dilute the price but also inhibit the price runup. All from a company that refuses to give its investors any updates. And no-shows conferences with no public explanation given to its investors. No wonder Shorts have piled onto this, management makes it easy to create doubt with long periods of no pr.
-
If this touches 2.55 I’ll add more.
-
866-612-8937 ATOS
Inquire as to why no PR has been released, told them my vote will be no unless some type of PR is given prior to the shareholder meeting. Said they would have someone call me.
Enough people start blowing them up they will get the picture.
-
Clearly desperate to get the YES vote. They may be forced to drop the PR to get people to vote YES
-
They refuse to release one email with the promised trial updates due a month ago, but have emailed me a dozen times trying to get me to change my mind on my vote. Typical corporate greed.
-
In the proposed dilution, they have 15m shares allocated to bonuses. Additional compensation on this vote, etc. If they hit, fine but if they don't, we just paid to make them millionaires.
Vote NO to diluting the stock
-
They have called me 4 times about my voting No.
-
Frank, at this point an “average up” means nothing if you are expecting the stock to go to $20. Now it’s about acquiring as many shares as you can before it runs. Out of my 26k shares at least 6k of them are “free” simply from swing trading it.
-
Like clockwork opening dip.
Sold 14k at 2.75 PMarket
Rebought at 2.56Holding 26k now.
Hoping we FINALLY get some PR today!!
Cmon Quay!!
-
Dilution adds 325 million shares to the Float. Who do you think is gonna buy those up? Hedge Funds. And Short the hell out of this.
-
Vote NO .
-
Doesn’t matter if Clay is on a bad streak, it’s still unwanted short activity
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •